SILDENAFIL CITRATE (sildenafil citrate) by Teva is pde-5 in the smooth muscle of the pulmonary vasculature, where pde-5 is responsible for degradation of cgmp. Approved for pulmonary arterial hypertension (pah) (world health organization [who] group i) in adults to improve exercise ability, delay clinical worsening.
Drug data last refreshed 1mo ago
PDE-5 in the smooth muscle of the pulmonary vasculature, where PDE-5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with PAH, this can lead to vasodilation of the pulmonary vascular bed…
Worked on SILDENAFIL CITRATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form
Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males
Study of Sildenafil Citrate on Insulin Resistance in African American
A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia